Validation of the San Francisco Syncope Rule
Procedure: Application of the San Francisco Syncope Rule
|Study Design:||Time Perspective: Prospective|
|Official Title:||Validation of the San Francisco Syncope Rule|
|Study Start Date:||January 2005|
This study was designed to validate the "San Francisco Syncope Rule". This set of rules was derived by Quinn et. al. to help guide the treatment of patients evaluated in the Emergency Department who had an episode of syncope or near syncope.
A rule that considers patients with an abnormal ECG, a complaint of shortness of breath, hematocrit less than 30%, systolic blood pressure less than 90 mm Hg, or a history of congestive heart failure was shown predict with a good degree of accuracy which patients would have an adverse event/serious outcome and require admission. Serious outcomes include the following: death,myocardial infarction, arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, significant hemorrhage, or any condition causing a return ED visit and hospitalization for a related event.
In Quinn's derivation trial, the sensitivity of the rule was 96%.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00300625
|United States, New York|
|Montefiore Medical Center|
|Bronx, New York, United States, 10467|
|Principal Investigator:||Adrienne J Birnbaum, MD||Albert Einstein College of Medicine of Yeshiva University|
|Study Chair:||E J Gallagher, MD||Montefiore Medical Center|